1. Home
  2. VIR vs CII Comparison

VIR vs CII Comparison

Compare VIR & CII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIR
  • CII
  • Stock Information
  • Founded
  • VIR 2016
  • CII 2004
  • Country
  • VIR United States
  • CII United States
  • Employees
  • VIR N/A
  • CII N/A
  • Industry
  • VIR Biotechnology: Pharmaceutical Preparations
  • CII Investment Bankers/Brokers/Service
  • Sector
  • VIR Health Care
  • CII Finance
  • Exchange
  • VIR Nasdaq
  • CII Nasdaq
  • Market Cap
  • VIR 1.0B
  • CII 860.9M
  • IPO Year
  • VIR 2019
  • CII N/A
  • Fundamental
  • Price
  • VIR $7.12
  • CII $19.76
  • Analyst Decision
  • VIR Buy
  • CII
  • Analyst Count
  • VIR 5
  • CII 0
  • Target Price
  • VIR $36.40
  • CII N/A
  • AVG Volume (30 Days)
  • VIR 1.6M
  • CII 78.8K
  • Earning Date
  • VIR 10-31-2024
  • CII 01-01-0001
  • Dividend Yield
  • VIR N/A
  • CII 6.17%
  • EPS Growth
  • VIR N/A
  • CII N/A
  • EPS
  • VIR N/A
  • CII N/A
  • Revenue
  • VIR $78,618,000.00
  • CII N/A
  • Revenue This Year
  • VIR N/A
  • CII N/A
  • Revenue Next Year
  • VIR N/A
  • CII N/A
  • P/E Ratio
  • VIR N/A
  • CII N/A
  • Revenue Growth
  • VIR N/A
  • CII N/A
  • 52 Week Low
  • VIR $6.56
  • CII $16.76
  • 52 Week High
  • VIR $13.09
  • CII $19.81
  • Technical
  • Relative Strength Index (RSI)
  • VIR 38.72
  • CII 52.99
  • Support Level
  • VIR $6.56
  • CII $19.53
  • Resistance Level
  • VIR $10.13
  • CII $19.69
  • Average True Range (ATR)
  • VIR 0.56
  • CII 0.19
  • MACD
  • VIR -0.29
  • CII -0.01
  • Stochastic Oscillator
  • VIR 14.43
  • CII 49.87

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

About CII Blackrock Capital and Income Fund Inc.

Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its objective is to provide total return through a combination of current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its total assets in a portfolio of equity securities of U.S. and foreign issuers.

Share on Social Networks: